welcome back, have to admit, all these little (and big) deals are catching me off guard. the latest is evidence that amgen is planning on om being a world wide blockbuster and they are setting themselves up to see it through. i am more bullish now than i have ever been on our long term prospects.
BF. Thanks but I am Not back yet. In Edinborough. T in the Park was huge today. Nice action with CYTK. OM IV data must be showing significance on most end points. On the oral side I also wonder if the software randomization glitch was not so random. It seemed obvious that the steering committee wanted a higher patient enrolment to obtain more rigor. This seems well timed...
I think the real news is that OM is going to Phase III. That has to mean a royalty payment from Amgen. I'd like to know the timing and amount of that... and, I've been forever curious, why is it such a big secret? Who is harmed by laying out the royalty schedule?
It kind of reminds me of Amgen's start up days, when they sold J&J the international rights to Epogen, their first drug, because Amgen had no international presence. This is Amgen's first cardiac drug.
What's more important is that it further confirms to me that the OM phase 2 trial was successful. I don't think Servier would have given up US rights to their successful cardiac drug to get OM, if they had not been shown the results of the trial. And Amgen knows the synergistic effects of those two drugs will create a Lipitor-like franchise for them. The insurance companies are desperate for a way to keep the millions of chronic heart failure patients out of the hospital, especially given our demographic future. They will pay up. I have also bought Amgen, because I think they are going to steal CYTK for peanuts.